Lachmann, N <br/><br/>
Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy.  [electronic resource] 

 -  Leukemia  Nov 2015 
 - 2266-9 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2015.108  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--adverse effects<br/>Bone Marrow--drug effects<br/>Cladribine--adverse effects<br/>Cytarabine--adverse effects<br/>Cytidine Deaminase--physiology<br/>Deoxycytidine Kinase--genetics<br/>Drug Resistance, Neoplasm<br/>Genetic Therapy<br/>HL-60 Cells<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Vidarabine--adverse effects